NCT05037305: MPRINT

VICE-MPRINT: Maternal and Pediatric Pharmacogenetics Survey

Active, enrolled NA Last updated 10 March 2026

What this trial tests

NA trial testing Educational video in Pharmacogenomic Testing in 500 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

30 June 2022

Primary endpoint
31 January 2026

30 April 2026

Quick facts

Lead sponsor	Vanderbilt University Medical Center
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	health services research
Enrollment	500
Start date	30 June 2022
Primary completion	31 January 2026
Estimated completion	30 April 2026
Sites	2 locations across United States

Drugs / interventions tested

• Educational video

Conditions studied

• Pharmacogenomic Testing — all drugs for Pharmacogenomic Testing →

Sponsor

Vanderbilt University Medical Center

Who can join

Eligibility, any sex, with Pharmacogenomic Testing. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The field of pharmacogenetics has progressed from the discovery of genetic variants that cause variable function of drug metabolism enzymes to a cornerstone of clinical precision medicine. However, there are limited data supporting drug-gene associations for children and for women during and after pregnancy. The unique physiology of childhood and pregnancy demand validation of pharmacogenetic signals prior to clinical implementation. These knowledge gaps are compounded for individuals from minority populations, who have been underrepresented and thus underserved by genomic research and specifically pharmacogenetic studies. The primary objective of this project is to advance research and support clinical implementation in pharmacogenetics for children and pregnant women. This work will illuminate knowledge of, attitudes about, and priorities for pharmacogenetics, and will assess the impact of a brief educational video on knowledge and attitudes around pharmacogenetic testing. The investigators will assess the knowledge and attitudes regarding pharmacogenetic testing among diverse cohorts of children with chronic conditions and pregnant women, before and after receiving pharmacogenetic test results. Participants will be randomized to view an educational video about pharmacogenetic testing either at the time of receiving their pharmacogenetic test results, or at a later time. The investigators will perform surveys before and after pharmacogenomic testing and return of results, and before and after watching the educational video.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. Tutorial: Using Community Engagement Studios to Enhance Pharmacogenetic Study Design for Maximizing Enrollment of Diverse Children and Pregnant People.
   Jasper EA, Holley SE, Jones SH, Liu M, et al · · 2023 · cited 3× · PMID 36366911 · DOI 10.1002/cpt.2792
2. A randomized trial to evaluate attitudes regarding pharmacogenomics among pregnant and pediatric populations: design and baseline characteristics.
   Sundermann AC, Marryshow Batson SE, Jasper EA, Jones SH, et al · · 2026 · PMID 42026028 · DOI 10.1038/s41397-026-00413-5